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Barrett’s oesophagus is a metaplastic condition with an inherent risk of progression to adenocarcinoma. It
is essential to identify dysplastic changes within Barrett’s oesophagus in order to individualise surveillance
strategies and establish which patients warrant endoscopic treatment. There is a trend towards endo-
scopic resection of focal high-grade dysplasia followed by whole segment ablation. However, endoscopic
identiﬁcation of dysplastic lesions is unreliable and subjective making targeted therapy extremely difﬁcult.
In addition, the current practice of taking random quadrantic biopsies may miss dysplastic disease and
intramucosal adenocarcinoma. Several advanced endoscopic imaging techniques have been described and
tested in clinical trials in an effort to improve the detection of early lesions, although none are routinely
used in clinical practice. In this article we will review these techniques and discuss their potential for
clinical implementation. We will also discuss the potential beneﬁts of multimodal imaging and highlight
several newer techniques which have shown early promise for in vivo diagnosis.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The incidence of oesophageal adenocarcinoma in the Western
World has increased by 500% over the past 40 years.1,2 Signiﬁcantly,
survival rates have failed to improve during this period and
outcomes for symptomatic cancers remain bleak with 5 year
survival ﬁgures of just 8%e15%.3,4
Early detection of premalignant high-grade dysplasia (HGD) is
essential to improve patient outcomes and prevent progression to
invasive malignancy.3 For this reason patients with Barrett’s oesoph-
agus are kept under endoscopic surveillance so that endoscopic
therapy can be instigated early in those with progressive disease.5
There has been tremendous progress in the endoscopic treat-
ment of Barrett’s neoplasia over the past decade. Endoscopic
resection of focal neoplastic lesions enables accurate histological
classiﬁcation of dysplasia, improves detection of synchronous
intramucosal cancers (IMC) and can achieve complete eradication
of dysplastic lesions in 82.5%e95% of patients with high-grade
dysplasia (HGD).6e9
Increasingly clinicians are favouring a policy of endoscopic
resection of visible early neoplastic lesions (IMC (T1a adenocarci-
nomas) and HGD) followed by whole segment ablation to destroy
the neoplastic ﬁeld change. This approach has been shown to
reduce recurrence rates compared to single modality therapy.10
However, these essential diagnostic and therapeutic beneﬁts ofax: þ44 08454 225480.
nd).
ciates Ltd. Published by Elsevier Ltendoscopic resection are only possible where lesions are detectable
endoscopically.
Endoscopic detection of Barrett’s neoplasia is notoriously difﬁ-
cult using conventional white light endoscopy. A variety of diag-
nostic endoscopic techniques have been developed in an attempt to
improve the accuracy of neoplasia recognition in Barrett’s
oesophagus and enable targeted biopsy or endoscopic resection
(ER) of neoplastic lesions. This article reviews the evidence-base
that supports the better established diagnostic techniques and
discusses their prospective role in clinical practice, including the
potential for multimodality imaging. With an eye further to the
future several alternative novel tools in early stages of clinical
development are also reviewed.
2. Endoscopic approach to Barrett’s oesophagus
A thorough and systematic inspection of themucosa is essential.
Lavage should be performed using water or 1% acetylcysteine to
remove blood, saliva and reﬂuxate from the oesophagus and
adequate insufﬂation should ensure that any mucosal abnormali-
ties can be clearly inspected. Particular care must be taken to
identify the oesophagogastric junction in patients with a hiatus
hernia to avoid missing the distal extent of a metaplastic segment
in these patients. Endoscopists should also consider that the
majority of early neoplastic lesions arise between 6 o’clock and 12
o’clock in the endoscopic view.11
The endoscopic appearance of the Barrett’s segment should be
recorded using the Prague C&M criteria as deﬁned by thed. All rights reserved.
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records the lengths of the circumferential (C) and maximum extent
(M) of the Barrett’s segment. It is also essential that clinicians
record precisely the site of each biopsy as this may be important for
future endoscopic therapy and is crucial for correct histological
classiﬁcation. In addition, where possible lesions should be char-
acterised according to the Paris classiﬁcation (Table 1).
3. Endoscopic recognition of early neoplasia: The problem
Endoscopic recognition of dysplasia and IMC within Barrett’s
oesophagus is subjective and difﬁcult even for skilled endoscopists.
Progression to dysplasia or IMC in Barrett’s oesophagus is rare and
the lack of familiarity of most endoscopists with the typical
appearances of early neoplasia is a signiﬁcant limiting factor in its
detection.4,13e15 Guidelines therefore advise that multiple biopsies
are taken whenever Barrett’s oesophagus is identiﬁed at endos-
copy.5 Most endoscopists take four quadrant biopsies every 2 cm of
Barrett’s oesophagus, or fewer.
This policy samples less than 5% of the mucosa and maymiss up
to 57% of early neoplastic lesions.16 In addition, patients with HGD
are known to have a 30e40% chance of occult adenocarcinoma
which may be missed by sampling error in up to 50% of patients
when using a standard biopsy regimen. Several studies have
compared the results of endoscopic biopsy assessment to surgical
pathology following oesophagectomy for the detection of adeno-
carcinoma in dysplastic Barrett’s segments. Falk et al demonstrated
that over a third of cancers (38%) were missed when quadrantic
biopsies every 2 cm were taken from patients with HGD. Jumbo
biopsy forceps made little difference to detection rates (67% versus
62%).17 Cameron and Carpenter found 2/19 (10.5%) unsuspected
adenocarcinomas following quadrantic 2 cm biopsies in patients
who subsequently underwent oesophagectomy.18 Similarly, Reid
et al showed that this biopsy regimen would have missed 13/26
(50%) of cancers in their cohort. They also demonstrated that tar-
geted biopsies of endoscopically visible suspicious lesions were
only able to establish the correct diagnosis in 15 out of 45 (33%)
patients who were subsequently proven to have cancer.19
In addition to the sampling error of standard biopsy regimens
and the low sensitivity of targeted biopsies when using standard
white light endoscopy, diagnostic difﬁculties are further com-
pounded by limited inter-observer agreement between patholo-
gists (k¼ 0.2e0.6), especially for distinguishing HGD from LGD.20,21
There is a clear clinical need for advanced imaging tools that
could improve endoscopic detection of HGD and IMC and enable
targeted treatment.
4. Wide-ﬁeld detection techniques
4.1. High resolution endoscopy
Modern high resolution endoscopes which generate up to one
million pixel images (compared to the 300,000 pixel images ofTable 1
Paris classiﬁcation of superﬁcial (0) lesions. Most dysplastic Barrett’s lesions are
type 0-II.
0 Superﬁcial lesions
0-I Protruding / polypoid lesions
0-Ip Pedunculated
0-Is Sessile lesions
0-II Non-protruding / non-excavated lesions
0-IIa Slightly elevated
0-IIb Completely ﬂat
0-IIc Slightly depressed
0-III Excavated / ulcerated lesionstraditional scopes) have been shown to have a higher sensitivity
than standard white light endoscopy for the detection of early
Barrett’s neoplasia provided they are used by expert endo-
scopists.22,23 So not to negate their effect these endoscopes should
be used in conjunction with a high deﬁnition television to further
enhance the projected image quality and prevent loss of resolution
when larger images are required.
Even in the hands of experts, Kara et al showed that targeted
biopsy using HRE was only capable of detecting 79% of dysplasia,
and differentiation from LGD for the purposes of targeted treat-
ment was difﬁcult.22 HRE should replace standard WLE where
possible. Although to signiﬁcantly improve endoscopic diagnosis of
dysplasia, HRE may be best utilised in conjunction with additional
endoscopic imaging technology.
4.2. Chromoendoscopy
Chromoendoscopy involves exogenous administration of stains
to the oesophageal mucosa in order to improve tissue character-
isation during endoscopy. Absorptive stains (such as methylene
blue) cross-epithelial membranes selectively, whereas contrast
stains (such as indigo carmine) permeate into mucosal crevices
highlighting surface topography and mucosal irregularities.24
Studies utilising chromoendoscopy in Barrett’s oesophagus have
had mixed results and have highlighted problems such as difﬁcul-
ties in uniformly coating the oesophageal mucosa with the stain,
and excessive times necessary for stain spraying.20,25,26 The tech-
nique has not been shown to consistently out-perform HRE in the
detection of early neoplastic lesions.27
Chromoendoscopy is relatively widely available and does not
require any particular equipment except for a spray catheter which
is easy to use and cheap to purchase. However, chromoendoscopy is
often both labour-intensive and operator-dependent and is there-
fore unlikely to become widely utilised.
4.3. Narrow band imaging
Narrow band imaging (NBI) illuminates the mucosa with blue
and green light in order to enhance the resolution of the mucosal
surface by relying on the principal that longer wavelengths of light
penetrate deeper into tissue than shorter wavelengths. Narrow
band blue light displays the superﬁcial capillary networks, while
green light displays the sub-epithelial vessels, and a combination of
the two images produces an extremely high deﬁnition image of the
mucosal surface allowing visualisation of subtle mucosal irregu-
larities and alterations in vascular patterns consistent with
dysplasia and IMC.28
NBI is a widely available technique which avoids the need for
staining or intravenous contrast agents. It has shown promise in
detection of dysplastic lesions when in the hands of experienced
users.29,30 A recent review of NBI with magniﬁcation demonstrated
high accuracy for the diagnosis of HGD in Barrett’s oesophagus
based on recognition of irregular mucosal pit patterns and/or
irregular microvascularisation.31 However, NBI is time-consuming
and results have been mixed due to high levels of inter-observer
variability.27,29 Overall, data on the accuracy of NBI in Barrett’s
oesophagus are inconclusive and results of multicentre randomised
controlled trials are awaited.
4.4. Autoﬂuorescence imaging
AFI detects ﬂuorescence radiation following excitation of tissue
using light of short wavelengths. Variation in the type and
concentration of ﬂuorophores enables differentiation between
normal, metaplastic and neoplastic tissue. Several studies have
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oesophagus although the technique appears limited by low spe-
ciﬁcity.32e34 Curvers et al demonstrated an increased detection rate
of HGD/IMC using AFI compared toWLE alone (53% Vs 90%) but this
came at the expense of a high false positive rate of 81%.35
Further trials are necessary to demonstrate improvements in
speciﬁcity through combination with other imaging techniques
such as confocal microscopy.
4.5. Optical coherence tomography
OCT is similar to ultrasound but can produce higher quality
images as it relies on backscattering of near-infrared light (as
opposed to radio waves) to generate cross-section images of
epithelial and sub-epithelial tissues.
OCT is performed using probes passed through the instrument
channel of endoscopes. It does not require the use of exogenous
contrast and, unlike with ultrasonography, tissue contact is not
required.
Several studies have assessed the role of OCT in the detection of
dysplasia. In a study of 55 patients with Barrett’s oesophagus, OCT
was shown to delineate between HGD and adenocarcinoma with
a sensitivity of 83% and a speciﬁcity of 75%.36 Another study of 33
patients demonstrated a diagnostic accuracy of 78% for the iden-
tiﬁcation of dysplastic Barrett’s oesophagus, however considerable
user discrepancy (56%e98%) was demonstrated.37
Further clinical evaluation is required to assess the diagnostic
performance of OCT in the oesophagus. In the future the technique
may have a greater role in the staging of early oesophageal tumours
rather than in the detection of dysplasia, however the considerable
time required to acquire and interpret the images may become
a signiﬁcant limiting factor.
4.6. Labelling of biomarkers
Visually tagged probe molecules have been engineered which
selectively bind to neoplastic cells.38,39 Lu et al identiﬁed a cell-
surface peptide speciﬁc to adenocarcinoma which they labelled
using a ﬂuorescein-tagged antibody delivered topically. The
oesophagus was then washed to remove any unbound antibody
and a ﬂuorescence endoscope was used to visualise neoplastic
disease.40
Similarly, Fitzgerald et al recently demonstrated that alterations
in cell-surface glycans during progression to adenocarcinoma could
be identiﬁed through changes in their lectin binding properties.41
Selective binding of a candidate lectin (wheat germ agglutinin)
sprayed into an ex vivo oesophagus enabled visualization of high-
grade dysplastic lesions, which were not detectable by conven-
tional endoscopy (Fig. 1B).
These highly promising molecular techniques require further
work in order to identify novel molecular targets to improve
sensitivity and speciﬁcity before clinical implementation can be
considered.
5. Point measurement techniques
5.1. Confocal microscopy
CM magniﬁes the mucosa 1000-fold enabling real-time visual-
isation of cellular structures. CM has shown considerable potential
in Barrett’s oesophagus with reported accuracy of up to 97.4% for
the detection of dysplasia.42 However, due to considerable inter-
user variation these results have not been universally matched.43
The technique has also been criticised for being both time-
consuming and expensive as well as requiring considerabletraining to interpret and relying on the use of exogenous contrast to
demonstrate the irregular neovascularisation that is characteristic
of neoplastic tissue. Further trials are required before this technique
can be recommended for widespread use.
5.2. Elastic scattering spectroscopy (ESS)
ESS uses a ﬁbre-optic probe passed through the instrument port
of an endoscope to generate morphological information about the
nature of the Barrett’s segment. White-light is elastically scattered
from the mucosa and submucosa with varying signal depending on
the size and shape of the cell nuclei and the degree of cellular
crowding.
Spectral signal can be acquired in short acquisition times which
approach ‘real-time’ imaging.
Dysplastic and malignant tissues have been shown to have
a characteristic ESS signature however, due to signal interference
from deeper structures the accuracy of ESS appears limited to
around 85%.44 Lovat et al measured spectra from 181 tissue sites
from 81 patients which were correlated with consensus histo-
pathology. ESS identiﬁed HGD with a sensitivity of 92% and
a speciﬁcity of 60% and was able to differentiate these sites
from inﬂammation with a sensivity and speciﬁcity of 79%.45
This current level of accuracy is probably not sufﬁcient to
support clinical uptake of ESS unless it can be improved through
reﬁnement of the technology or the use of a concomitant
imaging modality.
5.3. Raman spectroscopy
Raman spectroscopy relies on the principle of inelastic scat-
tering in order to generate a biochemical proﬁle of the oesopha-
geal mucosa (Fig. 1A). Neoplastic lesions have been shown to
display subtle changes in molecular composition which can be
detected and used to objectively classify the tissue.5,10,46e49
Although some way off wider clinical implementation, several
groups have recently conducted in vivo trials attempting to utilise
this technology endoscopically.48,50 Early results appear encour-
aging with Huang et al reporting overall accuracy of 96% for
detecting oesophageal adenocarcinoma.48 However, future work is
necessary to assess the diagnostic accuracy of RS for distinguishing
between LGD and HGD.
6. Discussion
Endoscopic detection of Barrett’s-associated HGD and early
adenocarcinoma is crucial to prevent missed disease and to enable
early curative endoscopic, or surgical, therapy. However, it is clear
that detection of early neoplasia in Barrett’s oesophagus is reliant
on a number of factors including the experience of the endoscopist
and their adherence with a comprehensive biopsy regimen. The
search continues for a one-stop technique that can accurately
identify and objectively grade neoplastic disease.
A variety of endoscopic imaging tools, at various stages of
development, have been trialled for use as diagnostic aids. None of
these have yet made the transition to widespread clinical practice
reﬂecting a variety of limitations including limited diagnostic
accuracy, considerable multi-user variation and long operator
times. In an attempt to address these difﬁculties several multi-
modality imaging systems have been described and have begun
evaluation in randomised trials.51,52 Curvers et al compared
detection of dysplasia using endoscopic trimodal imaging (ETMI)
and standard WLE in 99 patients who underwent both procedures
6e16 weeks apart. ETMI (HRE, AFI and NBI) was shown to improve
targeted identiﬁcation of dysplasia following detection of 22
Fig. 1. Novel endoscopic techniques currently in development. (A) Raman spectra for normal squamous mucosa (NSq), intestinal metaplasia (IM), HGD and adenocarcinoma
(Adeno). Each pathology has a slightly different spectral signature due to differences in biochemistry enabling objective diagnosis in 1 s or less. (B) Ex vivo oesophageal imaging.
Figure modiﬁed from Fitzgerald et al. NatMed 2012 with permission from RightsLink.41 ex vivo endoscope images using white-light endoscopy (left), and ﬂuorescence imaging after
application of a ﬂuorescently-tagged lectin (right). Areas of HGD, corresponding to areas of low lectin binding, appear purple. The dashed white line was used to orientate the image.
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overall neoplasia detection rates when compared to WLE plus
random biopsies, and its greater role may be in targeting neoplastic
lesions for endoscopic resection.53
Huang et al recently described a multimodal imaging system
combining endoscopic Raman spectroscopy with AFI, NBI and
standard white light endoscopy.54 This trimodal wide-ﬁeld imaging
systemwas used to guide point Ramanmeasurements of suspicious
areas and was shown to identify oesophageal cancer with a sensi-
tivity of 97.0% and speciﬁcity of 95.2%.48
The disadvantage of multimodality imaging systems such as
these is their expense, and the increase in time required to utilise
and interpret the different technologies. However, the principal of
combining wide-ﬁeld techniques with high sensitivity, and point
measurement techniques with high speciﬁcity is conceptually
promising.
It is perhaps unlikely that any of the techniques described will
become recommended for the assessment of Barrett’s oesophagusin non-specialist centres. Although the prevalence of Barrett’s
oesophagus in the West is increasing, the expense and training
required to support widespread use of additional endoscopic tools
may be impractical particularly given the low risk of neoplastic
progression.13e15
Surveillance strategies are likely to move towards inclusion of
only those patients deemed to be at a higher risk of progressive
disease. These patients may be identiﬁed based on long Barrett’s
segments (>5 cm), the presence of dysplasia, and potentially the
genetic proﬁle of the Barrett’s cells. Endoscopic technology would
then be utilised to aid targeted detection and treatment of early
lesions in these patients.
It is important to stress that the key to detecting early neoplasia
in Barrett’s oesophagus is a thorough and careful inspection of the
metaplastic segment supported by a sound knowledge of the
characteristics of suspicious lesions. The greatest role for additional
endoscopic technologies may prove to be in identifying these
lesions for targeted endoscopic therapy.
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